EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6,470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS

被引：0
|
作者：
Anliker-Ort, S. M. [1 ,2 ]
Berger, B. [1 ]
Kaufmann, P. [1 ]
Jana, L. [3 ]
van den Anker, J. [4 ]
Dingemanse, J. [1 ]
机构：
[1] Idorsia Pharmaceut, Allschwil, Switzerland
[2] Univ Childrens Hosp, Basel, Switzerland
[3] CEPHA Sro, Plzen, Czech Republic
[4] Univ Basel Childrens Hosp, Basel, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-054
引用
收藏
页码：S61 / S62
页数：2
相关论文
共 32 条
  • [21] Predicting the contribution of rat cytochrome P-450 3A1, 3A2 and human cytochrome P-450 3A4, 3A5 to territrem a 4beta-C hydroxylation using the relative activity factor
    Lin, Yu-Husan
    Peng, Fu-Chuo
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES, 2008, 71 (21): : 1407 - 1414
  • [22] A phase 1 non-randomized open-label study to evaluate the effect of Regorafenib on probe substrates of CYP 2C9 (Warfarin), 2C19 (Omeprazole), and 3A4 (Midazolam) in a cocktail approach (Group A) and on a probe substrate of CYP 2C8 Rosiglitazone, (Group B) in patients with advanced solid tumors
    Gerisch, M.
    Lettieri, J. T.
    Boix, O.
    Kelly, A.
    Nieschwitz, D.
    Sawyer, M. B.
    Lin, T.
    Diefenbach, K.
    Haffner, F. T.
    Radtke, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 288 - 289
  • [23] Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1)
    Dombi, Agnes
    Kaci, Hana
    Valentova, Katerina
    Bakos, Eva
    Ozvegy-Laczka, Csilla
    Poor, Miklos
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (05):
  • [24] ROLES OF HUMAN CYTOCHROME P450 1A2, 2C9, AND 3A4/5 ENZYMES IN DRUG OXIDATIONS MEDIATED BY METABOLICALLY INACTIVATED HUMAN HEPATOCYTES IN PREVIOUSLY TRANSPLANTED CHIMERIC MICE
    Yamazaki, Hiroshi
    Uehara, Shotaro
    Shimizu, Makiko
    Suemizu, Hiroshi
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [25] Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population
    Yousef, Al-Motassem
    Bulatova, Nailya R.
    Newman, William
    Hakooz, Nancy
    Ismail, Said
    Qusa, Hisham
    Zahran, Farah
    Ababneh, Nidaa Anwar
    Hasan, Farah
    Zaloom, Imad
    Khayat, Ghada
    Al-Zmili, Rawan
    Naffa, Randa
    Al-Diab, Ola
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (10) : 9423 - 9433
  • [26] Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population
    Al-Motassem Yousef
    Nailya R. Bulatova
    William Newman
    Nancy Hakooz
    Said Ismail
    Hisham Qusa
    Farah Zahran
    Nidaa Anwar Ababneh
    Farah Hasan
    Imad Zaloom
    Ghada Khayat
    Rawan Al-Zmili
    Randa Naffa
    Ola Al-Diab
    Molecular Biology Reports, 2012, 39 : 9423 - 9433
  • [27] Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
    Jenkins, Julian
    Williams, Daphne
    Deng, Yanli
    Collins, David A.
    Kitchen, Valerie S.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (01) : 67 - 76
  • [28] Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis
    Julian Jenkins
    Daphne Williams
    Yanli Deng
    David A. Collins
    Valerie S. Kitchen
    European Journal of Clinical Pharmacology, 2010, 66 : 67 - 76
  • [29] Interaction of mycotoxins zearalenone, α-zearalenol, and β-zearalenol with cytochrome P450 (CYP1A2, 2C9, 2C19, 2D6, and 3A4) enzymes and organic anion transporting polypeptides (OATP1A2, OATP1B1, OATP1B3, and OATP2B1)
    Kaci, Hana
    Dombi, Agnes
    Gombos, Patrik
    Szabo, Andras
    Bakos, Eva
    Ozvegy-Laczka, Csilla
    Poor, Miklos
    TOXICOLOGY IN VITRO, 2024, 96
  • [30] Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials
    Dymond, Angela W.
    So, Karen
    Martin, Paul
    Huang, Yifan
    Severin, Paul
    Mathews, David
    Lisbon, Eleanor
    Mariani, Gabriella
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (02) : 175 - 184
1234